The short answer is yes – CB9 is currently legal in Austria, but that will change in 2026 when new legislation re‑classifies it as a controlled substance. Today the compound falls under the “novel psychoactive substances” exemption, allowing retailers to sell it without a licence. However, the Austrian Parliament has already voted on amendments to the Narcotics Act that will take effect on 1 January 2026, at which point possession, sale and importation of CB9 will become punishable offences. Consumers and businesses should therefore prepare now to avoid legal risks.
Current Legal Status
CB9 (cannabichromene‑9) is a synthetic cannabinoid that was introduced to the Austrian market in 2022. Because it is not listed in the official annex of the Narcotics Act, it is treated as a “new psychoactive substance” and is therefore exempt from the strict licensing requirements that apply to THC‑based products. Retailers can sell CB9 in headshops and online, provided they label the product as “not for human consumption” and do not make medical claims. This loophole is similar to the one that currently covers many CBD isolates.
Regulatory Changes Expected in 2026
The 2025 amendment to the Narcotics Act adds a specific entry for CB9, moving it from the exemption list to Schedule III. The key provisions are:
- Effective 1 January 2026, possession of any amount of CB9 will be a misdemeanor, punishable by up to six months in prison or a fine of €7 500.
- Commercial sale, import or export will be classified as a felony, carrying up to two years’ imprisonment and higher fines.
- Laboratories must report any detection of CB9 in consumer products to the Federal Office for Safety of Chemicals.
The change follows a EU‑wide review of novel cannabinoids that identified CB9 as having a high potential for abuse and limited therapeutic evidence.
Impact on Businesses and Users
For shop owners, the amendment means the current “lab‑tested but unregulated” model will disappear. Stock that is not cleared before the deadline will have to be destroyed or exported to a jurisdiction where CB9 remains legal. Consumers who keep personal quantities after 2026 risk criminal prosecution, even if the amount is for personal use. The market is likely to shift toward fully licensed medicinal cannabinoids or toward other non‑controlled analogues.
Compliance Recommendations
- Audit inventory – Identify all CB9‑containing products and plan a disposal or export strategy before 31 December 2025.
- Update lab testing – Ensure your analytical partner can distinguish CB9 from other cannabinoids, as future testing will be mandatory for any seized material.
- Train staff – Provide clear guidance on the upcoming legal status so sales personnel can answer customer queries accurately.
- Monitor legislation – The Austrian Ministry of Health publishes weekly bulletins on narcotics law; subscribe to stay ahead of any further amendments.
Frequently Asked Questions
Will possession of a small amount of CB9 be treated the same as larger quantities?
Yes. The 2026 law does not differentiate by weight; any amount is considered illegal, although first‑time offenders may receive reduced penalties under the misdemeanor provisions.
Can medical researchers still use CB9 after 2026?
Researchers may apply for a special licence from the Federal Ministry of Health. Such licences are granted only for scientifically justified studies and require secure storage facilities.
Are imported CB9 products subject to the same rules as domestically produced ones?
All imports will be subject to the same Schedule III restrictions. Importers must obtain a narcotics licence and file a customs declaration specifying the exact quantity.
How will law‑enforcement detect CB9 in products?
Standard forensic labs will use liquid chromatography‑mass spectrometry (LC‑MS) methods already validated for other synthetic cannabinoids. The new law obliges labs to report positive findings within 48 hours.
What alternatives can retailers offer once CB9 is banned?
Legally compliant alternatives include certified broad‑spectrum CBD, hemp‑derived THC under the 0.3 % limit, and any cannabinoids that remain outside the updated annex, such as CBG or CBC, provided they meet safety standards.